The Medical Laboratories company declared that revenue were Soft, in the October to December 31 2022 interval

For the October to December 31 2022 time-frame company lost money of $-0.08 per share compare to $-1.07 a year prior and grew loss from $-0.02 per share from the preceding financial reporting period.

The revenue declined substantially by -11.389 % to $5.70 million from $6.44 million in the corresponding financial reporting period a year prior and sequentially Revenue deteriorated by -12.477 % from $6.52 million.




In the October to December 31 2022 time-frame Psychemedics Corp reported net loss of $-0.688 million, instead of deficit of $-1.621 million in the corresponding financial reporting period a year ago.

PMD announced loss of $-1.08 million and revenue of $25.24 million in the fiscal 12 Months 2022.

Net loss per share has widen to $-0.19 from $-0.12 in the preceding fiscal year, while revenue increased by 1.33 % from $24.91 million a year prior.

Psychemedics Corp is expected to report next financial results on May 10, 2023.

Psychemedics's Capital Expenditures Growth

Psychemedics's Receivables Turnover Ratio

Other PMD's Earnings Reports

declared a slender top-line decline, in the financial interval closing Sep 30 2022